Peptides derived from trifluoromethylketones
US5567804A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 5, 1995 |
| Grant date | Oct 22, 1996 |
| Priority date | — |
| Expiry date | May 5, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of formula (I): ##STR1## in which: R.sub.1 represents alkyl or (C.sub.3 -C.sub.7) cycloalkyl R.sub.2 represents alkyl, or (C.sub.3 -C.sub.7) cycloalkyl, R.sub.3 represents hydrogen or alkyl, R.sub.4 represents halogen or alkyl or alkoxy, R.sub.5 represents alkyl, X and Y, which are different, represent CO or SO.sub.2, n represents 1, 2 or 3, p represents 0 or 1, Z represents sulfur or oxygen, A represents any one of the following groups: ##STR2## in which: A.sub.1 represents, with the nitrogen and carbon atoms to which it is attached, a mono- or bicyclic heterocycle, .cndot. or, ##STR3## in which: R.sub.6 represents hydrogen, alkyl or cycloalkyl or 2-indanyl, R.sub.7 represents hydrogen or alkyl, which compounds of formula (I) comprise thereof corresponding hydrates of the ketone function COCF.sub.3, the enantiomers, diastereoisomers and epimers thereof and the addition salts thereof with a pharmaceutically acceptable base and medical products containing the same are useful as HLE inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.